192 related articles for article (PubMed ID: 28721456)
1. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Karasic TB; Rosen MA; O'Dwyer PJ
Cancer Chemother Pharmacol; 2017 Oct; 80(4):661-671. PubMed ID: 28721456
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
Kircher SM; Nimeiri HS; Benson AB
Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib in metastatic colorectal cancer.
Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
9. Molecular insight of regorafenib treatment for colorectal cancer.
Arai H; Battaglin F; Wang J; Lo JH; Soni S; Zhang W; Lenz HJ
Cancer Treat Rev; 2019 Dec; 81():101912. PubMed ID: 31715423
[TBL] [Abstract][Full Text] [Related]
10. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
Lee YC; Michael M; Zalcberg JR
Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Zhang WJ; Li Y; Wei MN; Chen Y; Qiu JG; Jiang QW; Yang Y; Zheng DW; Qin WM; Huang JR; Wang K; Zhang WJ; Wang YJ; Yang DH; Chen ZS; Shi Z
Cancer Lett; 2017 Feb; 386():100-109. PubMed ID: 27864115
[TBL] [Abstract][Full Text] [Related]
12. Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Mirantes C; Dosil MA; Eritja N; Felip I; Gatius S; Santacana M; Matias-Guiu X; Dolcet X
Eur J Cancer; 2016 Aug; 63():74-87. PubMed ID: 27288872
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
Aprile G; Macerelli M; Giuliani F
BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
[TBL] [Abstract][Full Text] [Related]
15. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
16. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
Clarke JM; Hurwitz HI; Rangwala F
Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib as treatment for patients with advanced hepatocellular cancer.
Thillai K; Srikandarajah K; Ross P
Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
[TBL] [Abstract][Full Text] [Related]
18. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor.
Tomida C; Nagano H; Yamagishi N; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
J Med Invest; 2017; 64(3.4):262-265. PubMed ID: 28954993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
